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ABSTRACT
Stroke is the world's leading cause of adult disability, caused by lack of oxygen and
nutrients to the brain due to a blood clot in a major artery. This leads to ischemic damage of
neuronal cells that leads to paralysis, motor, and speech deficits. While most stroke therapies aim
at removing or reducing the blood clots in the brain, few treatments target cell damage.
Neuroglobin (NGB) is a protein in the brain that is able to aid in neuroprotection following
oxidative stress. Hypoxia-Inducible Factor-1 (HIF-1) is a transcription factor that serves as a
marker for cell recovery after hypoxia or low oxygen levels. Exosomes are microscopic
extracellular vesicles that can help deliver proteins across the blood-brain barrier. This thesis
focuses on finding a correlation between exosomal-delivered neuroglobin to ischemic cells and
the regulation of HIF-1 in order to develop an innovative treatment using exosomes. The specific
aims of this thesis are as follows:
Aim 1: Package NGB in exosomes of healthy cell
The XPAK-NGB plasmid will be used to transfect NGB DNA into wild-type human
embryonic kidney (HEK-293 cell line) cells. Exosomes will be harvested from the spent media.
The exosomes will be analyzed to ensure that the protein is packaged inside the exosomes.
Aim 2: Determine the limit of hypoxic conditions and effects of NGB on damaged cells
A literature review will be performed to determine the ideal concentration of H2O2 for the
survival of neuronal cells. This will include the composition of hypoxia as well as the length of
time that cells can be exposed to and remain viable.
Aim 3: Correlate NGB concentration and HIF-1 concentration
Another literature review will determine the specific markers of NGB and HIF-1.
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BACKGROUND AND SIGNIFICANCE
Stroke
Stroke is a common, incurable medical emergency that affects more than 200,000 people
every year, making it the fourth most leading cause of death in the United States [1]. Even
though the rates of incidence for stroke are decreasing worldwide, it is still the leading cause of
adult disability [2] and the fourth leading cause of dementia [3]. Approximately 3% of the adult
population has had a stroke, which equates to around 7 million people in the U.S. [3]. Every
year, there is an average of 800,000 strokes, with about 200,000 of these being recurrent strokes
[3]. Epidemiological studies show that men are 24-30% more likely to experience a stroke, but
more women overall have strokes as women tend to outlive men [3]. The decrease in stroke rate
is also higher for men, with a 26% decrease for men and a 23% decrease for women between the
years of 1997 and 2006 [3]. However, as the worldwide population continues to age, the
incidence of stroke is expected to rise once again [3]. There are two types of strokes: ischemic
and hemorrhagic. Ischemic strokes make up about 85% of all strokes. They are characterized by
the occlusion of a major artery in the central nervous system (CNS), causing a decrease in
oxygen to a particular part of the brain [2]. Hemorrhagic strokes are due to the bursting of a
blood vessel and the accumulation of bleeding in the brain [2]. The focus of this research will be
on ischemic stroke. Many risk factors for stroke have been identified, including hypertension,
diabetes, smoking, and obesity [2]. Treatments for stroke mainly focus on managing symptoms
and preventing additional strokes. These include thrombolytic therapy and antiplatelet treatment.
Preventative treatment to decrease the incidence of a primary stroke has become the focus of
much research surrounding stroke.
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While the efficacy of these detection methods is significant once stroke occurs, there still
exists a lack of viable diagnostic techniques to identify those at risk for stroke early. Therefore, it
is imperative to conduct research that can improve upon current diagnostic methods. The hope is
to be able to diagnose stroke early enough to administer the proper treatment.
Clinical Diagnosis of Stroke
Stroke has a very accurate rate of diagnosis, with about 92% of strokes being diagnosed
correctly [4]. Stroke must be diagnosed immediately to improve the prognosis of the patient and
ensure that the resulting treatments can be performed [4]. Typically, the disease occurs in
individuals above the age of 55, though younger children may be affected in more rare cases [3].
Stroke is diagnosed using a variety of methods, including brain imaging (computed tomography
scan), laboratory tests, and physical examinations [2]. Below is a compilation of the most
common physical symptoms of stroke that have been defined in the National Institute of Health
Stroke Scale (NIHSS).
1) Facial paralysis is when one side of the face droops during a stroke. This can be
identified by a noticeable drooping of the lips when the patient is asked to smile.
Currently, it is unknown why only one side of the face experiences paralysis [5].
2) Motor deficits, such as arm weakness, are also characteristic symptoms of a stroke. The
pronator drift is the standard method of evaluation to determine if the weakness is
significant [2]. The patient will be asked to raise both arms above their head and hold this
supinated position for 20 to 30 seconds. Patients with a motor deficit will be unable to
hold this position equally.
3) Dysarthria or slurred speech is another identifiable symptom of a stroke patient where the
patient affected is unable to repeat a simple sentence. This can also be a side effect of the
2

symptoms mentioned above, such as facial paralysis and muscle weakness. This
symptom could manifest in aphasia, which is a more permanent speech problem [5].
Most of these symptoms occur due to the damage of nerves and neurons that control muscle
movement and speech centers. It also depends on the region of the brain that is affected [5].
Nevertheless, it is relatively simple to identify these preliminary signs of stroke, and there have
been many acronyms designed to help bystanders recognize symptoms [4]. For example, an
acronym, FAST, is defined as (F)- facial paralysis, (A)- arm weakness, (S)- speech problems,
and (T)- time to act and call 911 [5]. These easy mnemonics can help diagnose the disease early
to allow the stroke patient to get the treatment they need.
Clinical Treatment of Stroke
Currently, the treatment of stroke focuses on pharmacological options; however, there are
also surgical solutions that have had much success. The main treatment options are thrombolytic
therapy, antiplatelet treatment, and rehabilitation.
Thrombolytic therapy breaks down the blood clots found in major arteries leading to the
brain [6]. For maximal success, this therapy must occur within 4.5 hours after the onset of
symptoms [2]. Many drugs are used for thrombolytic therapy, including alteplase, anistreplase,
urokinase, streptokinase, and many more [7]. These drugs are plasminogen activators, which will
trigger a cascade that dissolves the blood clot through fibrinolysis [7]. Antiplatelet therapy is a
preventative measure used to reduce the chance of a subsequent stroke. With an ischemic stroke,
the antiplatelet drug of choice is clopidogrel, but aspirin can also be taken if necessary [8]. These
drugs prevent the accumulation of platelets in a major vessel by inhibiting the enzyme
cyclooxygenase 1 (COX-1) [8]. However, there is a high internal bleeding risk with the use of
antiplatelet drugs, so patients must be monitored closely [8]. Rehabilitation is a strategy used to
3

help stroke patients return to their initial level of neurologic activity. It has been shown that
motor activity can be recovered relatively quickly after the onset of a stroke; however, speech
deficits take some more time to recuperate [9]. Rehabilitation should be initiated immediately
after the stroke (24-48 hours window) with a shorter session [9]. There has been no evidence that
suggests that intensive rehabilitation causes improved recovery, and the ideal amount of
rehabilitation has not been determined [9].
Neural Recovery After Stroke
After a stroke, the neural recovery process is time-consuming and continues for months
post-stroke. There are many mechanisms that the brain employs spontaneously in order to
maximize recoveries, such as axonal sprouting and molecular cascades. Most of these recovery
mechanisms are non-invasive and occur on their own. Recently, findings have shown that neural
recovery is not as proportional as was once thought [10].
Axonal sprouting is when healthy neurons try to send out signals to determine where
connections were lost due to ischemia [11]. Once the locations of these connections have been
evaluated, the neurons start to send out new axons in these directions to restore the old
connections [11]. Growth and differentiation factor 10 (GDF10) is a significant component in
activating axonal sprouting [11]. Additionally, many molecular cascades are prompted by
ischemia. These cascades promote inflammation or can even upregulate genes for growth factors
and angiogenesis to aid in tissue repair [12]. Recovery from stroke occurs in waves. Initially,
repair mechanisms are focused on reviving the damaged tissue. Then, weeks and months after
the stroke, spontaneous repair mechanisms are introduced to help with neural recovery. Finally,
the third wave of repair is maintaining a stable state after spontaneous repair. Even though this
state remains steady, changes to the structure and function of the brain are still possible [12].
4

Neuroglobin
Neuroglobin (NGB) is a 17 kDa protein that makes up part of the globin family with
other proteins such as hemoglobin and myoglobin [13]. Even though the sequence homology of
NGB with hemoglobin and neuroglobin is only 21-25%, the central amino acid residues for its
oxygen-carrying activity are conserved between all three structures [14]. It is present in the
central and peripheral nervous system and helps to protect neural structures in cases of hypoxia
and injury [13]. Hypoxia is a condition that leads to a decrease in oxygen concentration in cells.
Additionally, NGB helps channel oxygen into the mitochondria in order to improve cellular
respiration [13] and can also neutralize reactive oxygen species (ROS) [15].
Generally, NGB has been shown to be localized near actively metabolizing cells and
specialized neurons, such as the hypothalamus [15]. Moreover, the retina is one of the most
susceptible to oxidative damage, and therefore, there is a high concentration of NGB near this
structure [15]. Hypoxia and ischemia are modulators that increase the concentration of NGB in
the nervous system [15].
The presence of oxygen and glucose are integral to the proper functioning of the brain.
Oxygen has the ability to bind reversibly to the hexacoordinated iron protein, which then delivers
it to the cells [15]. Even though the specific mechanism of its action is currently unknown, much
research has been conducted to determine a mode of action. NGB combats hypoxia with
conformational changes in its structure. Under normal oxygen conditions, NGB is in the Fe2+bound oxygen form. However, when hypoxic conditions are detected, the conformation changes
to ferric bis-His [16]. This tertiary structure conformation change is a significant component of
the protective activity of NGB. Ferric bis-His NGB can bind to lipid-rafts in the cell and also
heterotrimeric G𝛼 proteins, activating signal transduction pathways [16]. Once G𝛼 has been
5

activated, this leads to an increase in cAMP concentrations intracellularly, which can help
protect the cell from cell death [16]. Additionally, human NGB that is in the ferric (Fe3+) form
acts as a guanine dissociation inhibitor (GDI) protein. GDI's bind to small GTPases to counteract
exchanges and prevents it from accumulating in the membrane, inhibiting its action [17].
The primary function of NGB is to protect against hypoxia and ischemia, but it can also
protect against cell death by increasing cAMP concentrations. Previous studies that observed the
effects of oxidative stress on NGB found that human NGB was transduced into cells [16]. Once
NGB was delivered to the cells, a cell viability assay was performed to determine that NGB
increased cell survival [16]. Therefore, NGB aids with cell vitality and adaptability under
oxidative stress conditions.
However, chronic hypoxia has been shown to lead to apoptosis. Chronic hypoxia will
oxidize NGB causing an accumulation of Fe3+ ions and cytochrome c, inducing apoptosis [14].
Cytochrome c helps maintain iron in the Fe2+ condition in normal physiological conditions.
Under oxidative stress, cytochrome c assists in oxidizing Fe2+ into Fe3+ in order to induce the
neuroprotective effects of NGB. Prolonged oxidative stress will degrade NGB and further
oxidize it, triggering apoptotic mechanisms [14].
NGB and Stroke
As NGB has been shown to have a role in hypoxia and ischemia, it is also involved with
ischemic strokes. Previous studies have demonstrated that there is an increase of NGB after
ischemic strokes in the brain, and it is primarily localized in the cortical peri-infarct region [18].
However, as this study was conducted in rodents, it is unclear whether this data can be
extrapolated to humans. In another study, it was found that polymorphisms, or mutations, in the
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NGB gene were related to a higher propensity of ischemic stroke in the Southern Chinese Han
population [19].
Even though the mechanism of neuroprotection of NGB from stroke is unclear, changes
in NGB expression do affect the severity of ischemic damage [20]. There have even been drugs
developed, like hemin, to increase the concentration of NGB in vitro [20]. The goal is that more
research can be conducted to cultivate drugs that involve NGB that function in vivo. As direct
delivery of NGB is unable to penetrate the cell, exosomal delivery is also an option and could
lead to a new treatment plan [21].
Oxidative Stress
Oxidation is a process that happens to all living creatures in nature, including our bodies,
and is a result of oxygen producing a physiological change in cellular structure and metabolism
[22]. The body produces toxic free radicals called reactive oxygen species (ROS) during
everyday activities like breathing, walking, and exercising [22]. In normal conditions, the body
produces antioxidants in order to balance ROS levels. However, in oxidative stress conditions,
the toxic free radical species are not detoxified by the body's defense system [22]. Prolonged
oxidative stress can lead to the development of many diseases, including neurodegenerative
diseases, cancer, atherosclerosis, and stroke [23].
Previous research has demonstrated a strong correlation between oxidative stress and
brain damage in stroke [23]. ROS targets the brain because it is composed of easily oxidized
lipids and expends oxygen at a higher rate than other organs [24]. This can lead to strand
breakage, sister chromatid exchange, DNA-protein crosslinking, and base modification [24].
With the accumulation of ROS, there is a decrease in adenosine triphosphate (ATP)
concentrations due to the lack of oxygen to perform aerobic respiration [23]. With this lack of
7

energy, calcium (Ca2+) builds up intracellularly and stimulates the activity of proteases and
lipases [23]. These enzymes play a critical role in the damage of brain tissue thereafter [23].
There has been extensive research performed on how to induce oxidative stress in vitro.
Oxidative stress results from prolonged hypoxia, so different methods have been found to
successfully lead to the hypoxic condition. A 100μM CoCl2 solution added to cellular media can
lead to hypoxia and will help activate factors for hypoxia [25]. The solution needs to stay
incubated in the media for 24 hours before any additional experiments are performed. Another
method is to expose the cells to hypoxia in a Modular Incubator Chamber [25]. This chamber can
change the level of oxygen gas that is present inside so that the cells can be fully exposed to the
lack of oxygen. The oxygen sensors present will allow for a more controlled change that will be
easier to measure as well.
In order to ensure that the cells are undergoing oxidative stress, there are specific markers
that can confirm hypoxia. These markers are upregulated in the presence of ROS and can be used
to determine the extent of oxidative stress [26]. These markers include IsoPs, MDA,
Nitrotyrosine, S-glutathionylation, MPO, OxLDL, and Serum antioxidant capacity [26]. Each of
these markers have their advantages and disadvantages, depending on the nature of the
experiment. While this is not a comprehensive list of markers, they are still a good starting point
to help determine the effects of oxidative stress.
Exosomes and the Blood-Brain Barrier (BBB)
Exosomes are a class of minuscule (30-100 nm) vesicles discharged from the cell that
contain proteins, DNA, RNA, and miRNA [27]. Exosomes are found in all types of cells and are
made up of components of the plasma membrane [27]. Specifically, in the brain, exosomes are
released by almost all cells [28]. These particles are able to communicate information between
8

neighboring cells, which in turn signifies that exosomes carry important physiological and
pathological data [27]. Exosomes are of particular interest because of their versatility, especially
with regards to the blood-brain barrier (BBB).
The blood-brain barrier is the junction where blood vessels meet brain tissue. This highly
selective barrier determines what is able to move into and out of the central nervous system
(CNS) [29]. It restricts the movement of many ions, molecules, and cells between the blood
system and the CNS [29]. However, exosomes can pass through the BBB, which poses some
powerful benefits [28]. Since the CNS is immensely regulated, the ability of exosomes to cross
this barrier allows researchers to gain more knowledge about the different types of cells inside
the CNS [28]. Additionally, not only can exosomes leave the CNS and travel throughout the
body, but they are also able to enter the CNS and target a particular cell [28]. Therefore,
exosomes provide many benefits in terms of research potential.
Exosomes are also widely used as drug delivery methods. Exosomes are able to fuse to
the membrane and deliver the protein cargo intracellularly [30]. First, exosomes join with the cell
membrane, and then they are ingested by the cell via endocytosis/phagocytosis [30]. The
exosomes enter the cell and are able to facilitate changes in physiology and pathology [30].
Exosomes are also cell-specific and are able to deliver proteins through long distances [30].
Drugs have been successfully delivered to the brain via exosomes, and uptake by the cell is
increased after certain cell surface modifications [30].
HIF-1
Hypoxia-Inducible Factor-1 (HIF-1) is a transcription factor that is made up of two subunits:
the HIF-1𝛼 and HIF-1 subunit [31]. The structure of the protein contains helix-loop-helix
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motifs and PER-ARNT-SIM (PAS) domains that aid in DNA binding and subunit dimerization
[31]. The protein has an average molecular weight of 93 kDa and is an oxygen-sensitive protein
located in all cells [31]. It helps to maintain homeostasis and promotes angiogenesis,
erythropoiesis, and glycolysis as part of the hypoxic response [31].
When there is a lack of oxygen, the HIF-1 concentrations increase dramatically.
However, under normoxic conditions, the protein is degraded via proteasomes [32]. As a
transcription factor, it allows the upregulation of genes such as vascular endothelial growth
factor (VEGF) and glucose transporters (GLUT) [32]. VEGF is a critical component of the
angiogenesis pathway, while GLUT is a transporter that introduces glucose into the cell for
metabolism. Along with other genes, these proteins help with the recovery process of cells.
HIF-1 is able to enter the nucleus and regulate gene transcription directly [33]. It is
present in all cells as a key regulator of oxygen responsiveness. Under high oxygen levels, the
HIF-1𝛼 subunit is marked for ubiquitination. It is identified by prolyl hydroxylases (PHDs),
which will hydroxylate the alpha subunit at proline residues [33]. This hydroxylated protein
recruits the von Hippel Lindau protein (VHL), which will target HIF-1 for ubiquitination and,
eventually, destruction [33].
Moreover, HIF-1 is involved in the survival response for cells under ischemic stress and
has been shown to be regulated by NGB. When NGB has been oxidized to the ferric state, HIF-1
is stabilized [14]. The HIF-1 gene has been recognized as part of the NGB promoter region so
that it may play a role in NGB expression [15]. However, other studies have shown that this
promoter region lacks the HIF-1 binding hypoxia response elements (HRE) [21]. While there is
speculation and uncertainty surrounding the exact relationship between HIF-1 and NGB,
previous studies have shown a strong correlation between the two proteins.
10

The presence of HIF-1 after oxidative stress is a marker that cell recovery has taken
place. It also allows the cell to be more resistant to future levels of stress by a mechanism of
ischemic preconditioning [33]. HIF-1 overexpression signals that ischemic protection pathways
have been activated to allow the cell to survive [34]. Nevertheless, prolonged exposure to HIF-1
has been shown to primate tumor metastasis and apoptosis [31]. Therefore, it is vital that
therapeutic treatments address a balance in HIF-1 concentrations.
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RESEARCH DESIGN AND METHODS
Aim 1: Package NGB in exosomes of healthy cells1
Aim 1.1: Collect XPAK – NGB DNA
In order to deliver NGB via exosomes, the DNA was obtained from the XPAK-NGB
vector. This vector packed the DNA inside of the cell, as opposed to outside the cell. E. coli cells
carrying this vector were grown and incubated overnight in three separate 50 ml conical tubes.
The DNA was isolated and purified using the QIAGEN QIAprep Spin Miniprep Kit [35]. After
an overnight incubation, the cultures were spun down at 3000 rpm for 10 minutes. The pellet was
resuspended in 1 ml of molecular grade water. Then, the sample was spun down once again at
13,000 rpm for 1-1.5 minutes. The pellet was resuspended in 250 ml of P1 suspension buffer,
250 ml of P2 lysis buffer, and 350 ml of N3 neutrality buffer. The sample was again spun down
at 13,000 rpm for 1-1.5 minutes. The supernatant was added to a DNA spin column and spun
again at 13,000 rpm for 1-1.5 minutes. The flowthrough was discarded and 800 µl of P.E. wash
buffer was added. The spin steps were performed again twice. 100 µl of E.B. elution buffer was
added to the column and incubated for five minutes. A final spin at 13,000 rpm was conducted
for 4-5 minutes to collect the DNA. A sufficient concentration of DNA was obtained before
proceeding to the next step, as confirmed with a nanodrop. DNA was stored at 4ºC.
Aim 1.2: Transfect HEK cells with XPAK-NGB DNA
A transfection is when foreign genetic material is introduced into the genome of a cell
[36]. Using Lipofectamine as the transfecting agent, the new DNA was delivered to the cell via

1

See Appendix for the detailed protocols for all of the experiments performed in Aim 1
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lipid vesicles. In this experiment, normal HEK-293 cells were first grown in T-75 flasks and
passaged into a 12-well plate as these cell types have been shown to overexpress NGB following
transfection [37]. About 150,000 cells were added to each well in the 12-well plate. After
reaching a 60-70% confluency, the cells were transfected using Lipofectamine-2000 and the
XPAK-NGB DNA from the miniprep. 125 µl of OptiMEM was added to 1 µl of Lipofectamine2000 and another 125 µl of OptiMEM was added to 1 µg of XPAK-NGB DNA. The two
solutions were incubated at room temperature for 10 minutes before being added together
dropwise. The tubes were then incubated again at room temperature for 20 minutes so the DNA
complex could form. The mixed solution was added to each well, dropwise and the plate was
placed in the incubator.
To confirm that the cells were transfected with NGB, immunocytochemistry (ICC) was
performed to visualize the success of the transfection. Six of the wells from the 12 well plate
were used for the ICC. Three wells from the transfected HEK-293 cells were used, while the
other three wells with the non-transfected HEK-293 cells were used to serve as a negative
control. The cells were fixed with 4% PFA and washed with PBS. A permeabilization solution of
0.5% Triton-X in PBS was added and incubated for 10 minutes at room temperature. A blocking
solution of 10% donkey serum in PBS was added to each well. Following a 30-minute incubation
at room temperature, the primary antibody (anti-NGB) was added to each well in a 1:500
dilution. The plate was incubated overnight at 4ºC. The following day, the wells were washed
with PBS (3 x 5 mins). The secondary antibody (TRITC) was added in a 1:1000 dilution and the
plate was incubated in the dark for 2 hours. Some PBS was added to each well before the cells
were taken for imaging. Fluorescence microscopy was performed on the cells to visualize NGB
packed within the cells.
13

Aim 1.3: Collect HEK XPAK-NGB exosomes
After a successful transfection, the exosomes were collected from the media. Three
separate media collections were performed: the first after 24-36 hours following the transfection
and two 24 hours after the previous collection. Exosomes were precipitated from this spent
media using 20% polyethylene glycol (PEG) and concentrated sodium chloride (NaCl). Nontransfected HEK exosomes were also harvested as a control. The tubes of spent media were spun
down at 10,000 G for 30 minutes at 4ºC. 20% PEG and 7.5 M NaCl was added to each conical
tube. The solutions were vortexed and incubated overnight. The samples were spun down at
10,000 G for 1 hour at 4ºC and the pellet contained the exosomes. It was resuspended in 500 µl
of 1X sterile PBS. The precipitated exosomes were stored at -80ºC for long-term storage.
Aim 1.4: Ensure that NGB is present in the exosomes
A dot blot was performed with the exosomes to determine that NGB protein was present
within the cells. 2 µl of both transfected exosomes and non-transfected exosomes were each
added to two nitrocellulose membranes. After the samples dried, the membranes were placed in
two petri dishes with blocking solution (5% BSA in TBS-T). The membranes were incubated at
room temperature for one hour on the shaker. The membranes were then washed in TBST before
the primary antibody was added (1:500 dilution in blocking solution). One membrane was
treated with the anti-NGB antibody while the other membrane was treated with the anti-CD63
primary antibody. The anti-CD63 antibody was used to ascertain that exosomes are present on
the blot. The dishes were incubated overnight at 4ºC.
After incubating, the membranes were washed with TBS-T and the secondary antibody
was added in a 1:10,000 dilution in the blocking solution. After a 1 hour incubation, the
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membranes are washed. Since the secondary antibody was conjugated to HRP, ECL solution was
used to induce visualization. The blot was read using a chemiluminescence imaging system (Gel
Doc).
Aim 2: Determine the limit of hypoxic conditions and effects of NGB on damaged cells
Aim 2.1: Research survival capabilities of neuronal cells in hypoxic environments
To better understand the hypoxic cellular limits of neuronal cells, web journals and peerreviewed articles from search engines such as Google Scholar and PubMed were reviewed. The
following terms were used in the search input: "Hypoxia," "Hypoxic conditions," "Cellular limits
for hypoxia," and "Neuronal cells." These articles were compiled and analyzed to determine the
best hypoxic conditions for neuronal cells that would allow for further research.
Aim 3: Correlate NGB concentration and HIF-1 concentration
Aim 3.1: Determine markers for the presence of HIF-1
A literature review for HIF-1 was conducted to determine its mode of action and also the
cellular changes that occur upon NGB induction. Journals were investigated to determine if there
were any specific markers for HIF-1 action and how they relate to NGB concentration under
hypoxic conditions. The databases were searched with some of the following terms: "HIF-1
markers", "HIF-1 action", "Neuroglobin and HIF-1". Higher levels of HIF-1 should be present in
ischemic cells to help facilitate recovery with neuroglobin.

15

RESULTS/DISCUSSION
Aim 1: Package NGB in exosomes of healthy cells
a)

b)

Figure Group 1: DNA Nanodrop Table
a) Nanodrop results from XPAK-NGB Clone 4; sample I.D. corresponds to the culture tube EX:
Clone 4 – X, where X is culture from which the DNA was purified b) Nanodrop results from
XPAK-NGB clone 4; sample I.D. corresponds to the bacterial culture tube EX: XPAKNGB Cl.4
– X, where X is the individual culture tube.

a)

b)
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c)

d)

Figure Group 2: HEK-293 ICC Fluorescence Microscopy Images
a) Wild-Type HEK cells images visualized with transmitted light (T.L.) b) Image 2a visualized
with fluorescence c) HEK-293 cells transfected with NGB DNA, visualized with T.L. d) Cells
from Image 2c visualized with fluorescence

a)

b)

Figure Group 3: Dot Blot Results
a) Experimental condition: Top row represents wild-type HEK-293 exosomes, and the bottom
row represents HEK-293 transfected with NGB DNA exosomes. The blots were treated with an
Anti-NGB antibody. b) Control blot: The top row represents wild-type HEK-293 exosomes, and
the bottom row represents NGB-transfected HEK-293 exosomes. This membrane was treated
with an Anti-CD63 antibody.
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Three separate experiments were performed to ensure that NGB was properly packaged
inside the cells and then inside the exosomes. A nanodrop was performed to determine how
much DNA could be administered to the cells for a transfection. After the transfection,
immunocytochemistry (ICC) was performed to make sure the cells did contain NGB in the cells.
Once the exosomes were precipitated, a dot blot was performed on the exosome sample to ensure
the exosomes also contained NGB.
Figure Group 1 shows the results from two separate nanodrop experiments. Both readings
were taken immediately following a bacterial miniprep. Figure 1a shows that the average
concentration of XPAK-NGB DNA from Clone 4 is 53.91 ng/ul. The A260/280 ratio measures
the purity of the DNA. Generally, a 260/280 ratio of 1.8 indicates pure DNA. The average
260/280 ratio for all the samples in Figure 1a is calculated to be 2.02. This value shows that the
DNA is not as pure as it could be. Additionally, the concentration is also relatively low.
As such, a subsequent experiment was performed with a new bacterial culture and a new
bacterial miniprep. Figure 1b shows the results of the second nanodrop performed from XPAKNGB DNA obtained from Clone 4. The average concentration of the DNA in this experiment
was 66.02 ng/ul. This is 12.11 ng/ul more than the concentration of DNA from Figure 1a. The
average A260/280 ratio of the data in Figure 1b is 1.99. While this is definitely closer to the
desired 1.8 threshold, it is still higher than preferred.
Various factors could have impacted the purity of the DNA. The reagents in the miniprep
process may not have been as free of contamination as the miniprep was performed on the bench.
Additionally, the bacterial culture could have been contaminated as well, even though most of
the contamination should have been extracted by the miniprep process. Another point of
contamination could have been during the nanodrop. Perhaps the blank of distilled water was not
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measured correctly. Alternatively, there may have been leftover contamination from the previous
run of the machine on the pedestals. While it may be difficult to pinpoint the exact reasoning for
the low purity, the higher concentration of the DNA will be beneficial to the completion of
further experiments.
Therefore, these nanodrop results from Figure 1b show that the XPAK-NGB DNA was
around 66.02 ng/ul, and bacterial culture tube 4 had the most relatively pure DNA. The average
A260/280 ratio for culture tube 4 was 1.94, which is the closest to 1.8 from all of the other
culture tubes. However, culture tube 2 had the highest average concentration of DNA at 78.36
ng/ul. To that end, both samples of DNA will be used in the transfection process to ensure high
concentrations and purity of the DNA being used.
Following the transfection, the immunocytochemistry protocol was performed. The
images from the microscope can be seen in Figure Group 2. Figure 2a shows wild-type HEK-293
cells imaged under transmitting light. This was done to check the health, morphology, and
confluency of the cells. The cells in the image are very confluent, almost around 90%
confluency. While the morphology is characteristic of other wild-type HEK-293 cells, the
confluency may cause some point mutations within the population of cells. This same batch of
cells was imaged with fluorescence to yield Figure 2b. The green portion should represent NGB
present within the sample of cells. Ideally, there should be no signal for the wild-type HEK-293
condition. However, there was a small signal present in Figure 2b. There are a few reasons why
this could have occurred.
First, there may inherently be NGB present in wild-type HEK cells; however, this has not
been investigated in the past. Additionally, it could be an error in the actual experimental
procedure. For example, if proper pipetting techniques were not used, a sample of the transfected
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cell line could have been introduced into the wild-type cell line, causing a slight signal.
Additionally, perhaps the antibody is recognizing some other contamination in the well, causing
the green color. The cells do look healthy, though, so it could also be due to imaging error. The
wild-type HEK cells are a negative control, so they should not have any signal. Even though
there is a little bit of signal, it will be compared to the experimental condition to determine the
success of the experiment.
Moving onto the experimental condition, Figure 2c shows the transfected population of
HEK cells that include NGB DNA. These were visualized under transmitting light to determine
the health of the cells. The cells themselves have the proper morphology, and they are a little bit
less confluent than the cells in Figure 2a— closer to an 80% confluency. There are some
diamond-shaped substances visible, which may be dried PBS. In Figure 2d, these cells are
imaged with fluorescence to determine if NGB is present within the cells. With the presence of
NGB inside the cells, the cells should show a green fluorescence color. In this figure, there is
fluorescence visible within the cells which means that NGB has been successfully packed inside.
While not all the cells are showing fluorescence, the majority of the cells do exhibit a signal, so it
can be confirmed that the transfection protocol was a success.
Comparing the set of images in Figure 2 shows that, even though Figure 2b shows a
small green signal, it is subdued compared to the fluorescence in Figure 2d. Therefore, even
though the non-transfected sample showed some NGB present, the transfected sample showed an
overexpression of NGB, which is needed to proceed with the experiment. Moving forward, the
exosomes precipitated from these cells should have NGB contained within.
After the exosomes were precipitated, the exosomes were added to a nitrocellulose
membrane, and a dot blot was performed. A dot blot was chosen instead of a more rigorous
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method because merely a confirmation of NGB presence was needed. A dot blot would be able
to determine that the exosomes themselves contain NGB. The results of the dot blot can be seen
in Figure Group 3.
Figure 3a shows the blot of the experimental condition that was treated with an anti-NGB
antibody. The top row of dots in the figure represents the wild-type HEK exosome control
samples. These exosomes have not been transfected with NGB DNA. The bottom row of dots
contains the HEK exosomes transfected with NGB DNA, which is the experimental condition.
There are duplicates of both samples to ensure that the results are valid.
Figure 3b shows the blot treated with the anti-CD63 antibody. CD63 is an exosomal
marker to ensure that exosomes are present on the blot. This blot was prepared as a positive
control to confirm the exosomal precipitation procedure. The top row contains the wild-type
HEK-293 exosomes, while the bottom row contains the HEK exosomes that were transfected
with NGB. These are the same exosomes that were used in the blot in Figure 3a. After
performing the dot blot, both blots were placed into a Gel Doc imager to visualize the results.
In Figure 3a, there was a signal present in both of the rows; however, the experimental
condition has a stronger signal. Figure 3b shows the positive control results, which follow what
was expected. There is an equal signal present in all four samples, demonstrating that all samples
consist of exosomes. As a control group, the housekeeping gene CD-63 helped identify the
presence of exosomes and not just any extracellular material. This means that the transfection
was successful and that the precipitated exosomes do contain higher levels of NGB than the
wild-type exosomes.
These findings also correlate with the earlier finding that there is some NGB present in
wild-type HEK cells. While the signal in the control condition was unexpected, it does follow the
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previous findings. However, the presence of this signal could also mean there were errors in the
data collection and procedure. The original HEK exosome samples could have been
contaminated with trace amounts of NGB. Additionally, the antibodies themselves could have
become contaminated, leading to small signals in the control group. It would be recommended to
reproduce this experiment to ensure that these results are representative of the condition of the
exosomes.
Overall, piecing together the various experiments, it can be confirmed that Aim 1 has
been fulfilled. NGB DNA was extracted, transfected into HEK-293 cells, and grown. The
exosomes were precipitated and analyzed to ensure that NGB has been packaged inside. The
results of the nanodrop, immunocytochemistry, and dot blot show that the exosomes do, in fact,
contain the NGB protein. While there were some potential errors in the results, subsequent
experiments did confirm the previous findings. Therefore, it will be established that the
exosomes have been packaged inside the exosomes of healthy HEK-293 cells.
Aim 2: Determine the limit of hypoxic conditions and effects of NGB on damaged cells
Table 1
Summary of Oxidative Stress Studies Reviewed
Study
Author(s)
#

2.1

BaccinoCalace et
al., (2019)
[38]

Study Purpose

Hypoxia
Conditions/Cell
Types

Limitations

To determine specific
cellular responses to
changing oxygen
conditions in the early
stages of Drosophila
development

The researchers
performed their
hypoxia experiments
on Drosophila larvae;
5% oxygen in nitrogen
was administered for
24 hours

Experiments were
performed on
Drosophila, so
they may not be
valid for humans
in vivo;
Drosophila neural
tissue was
examined rather
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2.2

2.3

2.4

Xu et al.,
(2020)
[39]

To analyze the
relationship between
oxygen-glucose
deprivation/reoxygenation,
neuronal cell death, LncD63785 methylation (noncoding RNA), and miR422a (microRNA)

SH-SY5Y
neuroblastoma cells
were cultured for this
experiment; 5% CO2
in nitrogen was
administered for 4
hours

than specific cell
types
Research involved
oxygen
deprivation along
with glucose
deprivation, which
is similar to stroke
conditions but not
within the scope of
this thesis; SY5Y
cells are cells that
are already
cancerous and may
show different
outcomes than
healthy neuronal
cells

E16.5 mouse cortical
cells were obtained
Research was
from embryos; 5%
performed on
To investigate the role of
CO2 in nitrogen was
mouse cortical
omega-3 polyunsaturated
administered for 4
cells, so it may not
Shi et al.,
fatty acid and
hours; cells that
be reproducible for
(2016)
Lyciumbarbarum
remained in the
humans; the cell
[40]
polysaccharide in recovery
chamber for more than type used was also
following OGD
24 hours showed a
very different than
reperfusion
marked decrease in
human neuronal
cell viability and
cells
number
Primary cortical
Again, this
neurons were cultured
experiment was
for this experiment;
focused on OGD
To determine how long
neurons were placed in conditions, so the
neurons can survive in
a chamber of 5% CO2 lack of glucose in
Zeiger et OGD conditions and how
in nitrogen for a
the chamber may
al., (2013) long it will take for further
maximum of 90 mins;
have skewed the
[41]
damage to become visible,
optimal range for cell results; the results
along with assessing their
health was determined of the OGD study
bioenergetic capabilities
to be 5-15 mins, after were measured 24
that, cell toxicity was
hours after the
measured
exposure to OGD
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2.5

Felfly et
al., (2013)
[42]

To resolve neuronal cell
limits in severe hypoxic
conditions and the effects
of prolonged hypoxia
exposure

Murine neural stem
cells (mNSCs) and
primary neurons were
The response of
used in this
mNSCs may not
experiment; 1%
be indicative of the
oxygen in 5% carbon
response to
dioxide to induce
hypoxia in the cell;
hypoxia for two days
this research does
(48 hours); in general,
not establish the
there was a significant
lower limit for
decrease in cell
hypoxia for
number after both
neuronal cells
types of cells were
exposed to hypoxia for
this period of time

Five different studies were hand-picked to help determine the limit of hypoxic conditions.
These studies were found on different platforms, but mainly on PubMed. Each summary for
hypoxia limits is summarized in Table 1.
Table 1 offers short descriptions of the selected research, including the study purpose,
results that are applicable, and limitations. Many of the studies' inherent purpose may not fit
within the scope of this thesis, but they were still selected because the procedures for hypoxia or
OGD (oxygen-glucose deprivation) were relevant to determining the conditions and duration of
hypoxia that can be administered. The results column explains what cell type was used, what
concentration of hypoxia/OGD was administered, and how long the cells were exposed to
hypoxia. Additionally, it will also list some preliminary effects of the hypoxia on the cells, if
appropriate. Finally, the limitations column will talk about how the research listed may not offer
some of the best insight into the aims for this thesis, including types of cells used and the
conditions of OGD.
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Study 2.1, listed in Table 1, was performed upon Drosophila to see how different oxygen
conditions could affect the neural development of the larvae [38]. The researchers exposed
Drosophila larvae embryos to 5% oxygen in nitrogen for 24 hours for their study. These
conditions allowed the larvae to survive, and the experimenters then dissected the larvae to
expose their brains. Therefore, these hypoxia conditions allowed the brains—and subsequently
the neurons—to remain viable. However, as these experiments were performed on Drosophila
larvae, these conditions may not translate over to humans. Additionally, individual cells were not
studied—rather, this study was focused on the brain as a whole with regards to the effects of
hypoxia. Nevertheless, this experiment is still helpful for the conditions of hypoxia and the
duration of exposure. This study will still need to be supplemented with another study that has
hypoxia performed on human neuronal cells.
Study 2.2 from Table 1 had the aim of analyzing the relationship between oxygenglucose deprivation (OGD) and reoxygenation (OGD/R) and neuronal cell death, in addition to
its effects on different RNA molecules [39]. This experiment used SH-SY5Y neuroblastoma
cells. These are cancerous human cells that were exposed to 5% CO2 in nitrogen for 4 hours.
These cells remained viable for the researchers to perform additional experiments. Additionally,
these cells were then "reoxygenated" by being placed in traditional media. However, this
research involved OGD conditions—which is representative of a stroke condition—but it is not
the focus of this research. SY5Y cells are cancerous as well, which means they may not be the
best representation of healthy neuronal cells. These cells could have different factors that alter
their response to low oxygen conditions. The condition of OGD cannot be used to determine how
to administer hypoxia because it is mainly CO2 rather than oxygen. Despite this, this study is still
helpful in determining the hypoxia limits for neuronal cells. Since SY5Y cells were used, 4 hours
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seems to be a safe duration for hypoxia administration. This duration will be confirmed with
another study that performs hypoxia—not OGD—on healthy neuronal cells.
Table 1 also lists Study 2.3, which studied different biological molecules and how they
were affected with OGD (fatty acids and polysaccharides) [40]. This experiment used E16.5
mouse cortical cells and exposed these cells to 5% CO2 in nitrogen for 4 hours. Other cells were
exposed for a more extended period of time. Cells that were exposed to OGD for more than 24
hours died or became less viable—even after reoxygenation. The cells that were used contained
the fat-1 gene, which may have affected the results. Additionally, the cortical cells of mice may
not garner reproducible results in humans. While cortical cells are part of the nervous system,
they may provide skewed results as they are not the primary cell of interest, nor are they the
organism of interest. However, this experiment does help to establish the upper limit of hypoxia.
Even though this study also used OGD/R, it can be assumed that 24 hours of exposure to low
oxygen conditions would cause irreparable harm to the cells. This study still provides valuable
data, especially when taken into account with the other studies. In conjunction with Study 2.2,
this study confirms that 4 hours seems to be an appropriate time to administer hypoxia, but this
will be corroborated with additional studies that are performed with hypoxia and on the right cell
type.
Study 2.4 gets closer to the preferred cell line. This study's purpose was to investigate the
response of cortical neurons to OGD, and it also looks into how long cells can be exposed before
further damage is elicited [41]. The neurons were exposed to OGD (5% CO2 in nitrogen) for up
to 90 minutes. It was found that the cells remained the healthiest after 5-15 minutes of exposure
to oxygen deprivation. Additionally, this study found that any incubation over 1 hour led to
significant cell death. However, it is important to mention that this study only measured the
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effects of OGD 24 hours post-exposure. Furthermore, as mentioned earlier, this experiment
focused on both oxygen and glucose deprivation, not only hypoxia, which may skew the results
for this thesis. Either way, it still provides an optimal range for human neuronal cells, especially
when compared to the previous studies.
Study 2.5 was used to reinforce the upper limit of hypoxia found from study 2.3—only
now will it be used with human cells [42]. The general aim of the study falls in line with this
thesis, and it was to determine the limits of neuronal cells in severe hypoxia and how prolonged
hypoxia may change cell morphology and other characteristics. This experiment used murine
neural stem cells (mNSCs) and primary neurons. These cells were exposed to hypoxia at 1%
oxygen in 5% CO2 for two days (48 hours). Both cell types had a decrease in cell number after
exposure for this long. Additionally, the NSCs became quiescent—unable to retain their
stemness. While the mNSCs may not provide accurate information on the response of neuronal
cells in human cells, the research on primary neurons is valuable. Additionally, while this study
does not offer insight into the lower limit of hypoxia exposure, it does provide the maximal limit
of 48 hours. Another benefit of this study was the conditions of hypoxia. While many of the
other studies performed OGD, this particular study researched hypoxia only, and this condition
will be helpful to extrapolate data.
Overall, all these five studies provide their advantages and disadvantages when taken into
consideration with the scope of this research thesis. First, even though many of the studies did
not test their hypotheses on human neural cells, these results can be combined to find out what is
the best condition and duration for hypoxia exposure. According to all the data from the five
studies, primary neurons survive the best when exposed to less than 1 hour of hypoxia with the
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best range between 5-15 minutes. The composition of the hypoxia was 1% oxygen in 5% CO2.
The cells will not be exposed for longer, and it will just be hypoxia, not OGD.
The original plan with this aim was to expose neuronal cells to hypoxia using an OGD
chamber. The cells would be exposed to hypoxia for a particular amount of time and then, NGB
would be introduced via exosomes to the stressed cells. In this aim, the goal would be to induce
hypoxia, perform some type of assay to ensure that hypoxia was properly administered, and then
add in the exosomes that have been transfected with NGB. The initial hypothesis was that NGB
will help these hypoxic cells recover from the lack of oxygen. Currently, this literature review
provides a good starting point to determine the composition of hypoxia as well as the period of
exposure.
Of course, since this was a literature review, these results are only accurate pending
actual experimentation. It is a good starting point for experiments, but the exposure to hypoxia
can only be accurately measured following exposure to hypoxia. Also, most of the studies were
based on hypoxia administered in vitro, and this may provide differing results in vivo.
Additionally, there were a diversity of cell types used, and these results may change depending
on which cell type is used in the experiment. Therefore, physical experiments must be performed
in order to ensure the reliability of these results. Overall, Aim 2 was satisfied as the cellular
limits of hypoxia were divulged after an extensive literature review.
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Aim 3: Correlate NGB concentration and HIF-1 concentration
Table 2
Summary of NGB and HIF-1 Studies
Study
#

Author(s)

Study Purpose

NGB/HIF-1 Findings
•

3.1

Wei et al.,
(2011) [43]

To understand the
role of NGB in
glaucoma as a
neuroprotectant

•

•

•

3.2

Brittain
(2012) [44]

To develop and
evaluate models for
how neuroglobin can
prevent preprogrammed cell
death

•
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Higher expression of
NGB in retinal
patients (which
experience more
oxidative stress)
reduces the intensity
of the effects of
stroke
transgenic mice and
retinal ganglion cells
were the subject of
this study
mitochondrial
function was
preserved while
superoxide
production
diminished
Early research found
the HIF-1 did not
regulate the
expression of
NGB—instead, κB3,
NFκB, and Sp1 help
upregulate NGB;
HIF-1 is involved but
has an indirect role
Proposed three
different models of
neuroglobin action:
oxygen model, the
nitric oxide model,

Limitations
This research was
performed on the
retinal cells of mice,
which is an entirely
different subject
matter, and the
results may not
apply to human
populations; the
research mentioned
it was difficult to
find evidence of
NGB action; in
order to increase
oxidative stress, a
higher intraocular
pressure was
manually
administered, which
could change the
findings.
This research
mainly evaluated
previous research
and found
connections
between them to
outline the various
findings in the field
for neuroglobin; no
physical experiment
was conducted to
determine how
neuroglobin acts or
the markers of
action

•

•

3.3

•
To investigate the
role of neuroglobin in
the nervous system
Baez et al.,
and how it mediates
(2016) [45]
the effects of various
pathologies in the
•
brain

•

3.4

Majmundar
et al.,
(2010) [46]

To focus on HIFs to
determine the
response to hypoxia •
and its regulation
based on other factors
•
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and protein-protein
interactions
The primary function
deals with
cytochrome c from
the mitochondria

NGB levels were
shown to remain
elevated for up to six
days after traumatic
brain injury (TBI)
Effects of NGB
include inhibition of
caspase 3 and 9,
activation of
PI3K/Akt pathway,
and increased GFAP
NGB interacts with
cytochrome c,
thyroid hormone T3
and is regulated by
NFκB, HIF-1,
erythropoietin, and
VEGF

HIF regulates
erythropoietin
expression and
transcription of other
factors involved in
the hypoxic response
pathway
Sirtuins and
intermittent hypoxia
are the best
regulators of HIF
activity
O2 sensors such as
PHDs, FIH1, and the
mitochondria may

This research
mainly focused on
astrocytes as the cell
type to relate to
NGB findings, not
providing a
diversity of results;
the research
outlined was mainly
focused on TBI,
with small mentions
of stroke, so the
premise of the
research may have
provided different
data in regards to
stroke research; no
physical experiment
was conducted to
determine these
results—it was a
summary of
previous research
This research
outlined HIF action
in various
physiological
system, not only the
nervous system, so
some findings may
not pertain to
hypoxia due to
stroke; not much
mention of
neuroglobin and the
relationship
between HIF and
NGB was made;

•

•

•

3.5

Hota et al.,
(2012) [14]

To understand how
different
configurations of
NGB can regulate the
activity of different
•
hypoxia factors,
including HIF and
Nrf2

•
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help kickstart HIF
transcriptional
activity
Different factors can
regulate various
subunits of HIF
Supports the role of
PHDs as oxygen
sensors to stabilize
HIF
Degradation of NGB
in the cell will, in
turn, decrease the
levels of HIF and
Nrf2, promoting
apoptosis
Rats were placed in a
hypobaric chamber
to simulate hypoxia,
and brains were
harvested and
analyzed
NGB inhibited
caspase 3 and
cytochrome c

again, this research
cites previous
studies that were
performed, but no
novel experiments
were performed to
support the data
The method of
hypoxia
administration is
very different than
what was discussed
in Aim 2—while
hypobaria may lead
to hypoxia, there are
many other
uncontrolled
variables; this
experiment was
performed on rats,
so it may not
provide the best
results for this thesis
focused on humans

Figure 4: Graph of Markers for NGB Action
Graph demarcates the results of Table 2, divided by each type of marker that was mentioned.
The horizontal axis reveals the different factors that were described to regulate NGB/HIF
activity. The vertical axis shows a count of how many studies outlined a particular marker as
involved in NGB/HIF regulation. The green vertical bar divides the data into two sets. The lefthand side relates to markers for NGB, while the right side relates to markers of HIF.
Evidence of the relationship between NGB and HIF-1 is well documented, but the
mechanisms of action are widely disputed, as well as the effects of neuroprotection by NGB on
the cell. To investigate this further, five different studies were chosen to elucidate the role of
NGB and HIF-1 and their respective cellular markers for action. As with Aim 2, these studies
were found in different journals. Table 2 summarizes the studies used, while Graph 1 compiles
all the data into an easy-to-understand visual of the different markers listed.
Table 2 lists the five different studies that were used to assess the relationship between
NGB and HIF. This table lists the purpose of the study, the markers that are correlated to
HIF/NGB, and the limitations presented by the studies. As with before, even though the study's
purpose may not be applicable to this thesis, some of the research findings were selected as they
fit within the scope of this research—though most of the research was connected to NGB/HIF.
The results show either the experiments or conclusions gathered from different studies, pieced
together. Many of the limitations listed in the final column have to do with the fact that no
physical experiment was performed; rather, much of the data was obtained from a thorough
literature review.
Study 3.1 provided a good baseline introduction to the role of NGB [43]. The study
focused on the effects of NGB in the retinal ganglion cells of transgenic mice. This study was
investigating NGB protection in glaucoma disease, but some findings did relate to stroke. For
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example, a higher level of NGB expression was found in retinal patients who experienced stroke.
This was shown to reduce the negative effects of stroke. Additionally, while the cell type studied
(retinal ganglion cells) is not the cell type of interest for this thesis, the cells used were still part
of the nervous system, so the correlation may be similar. However, to induce stress, the
researchers increased intraocular pressure (IOP), which is a marker of glaucoma. For this thesis,
this manual administration could have changed the mode of action of NGB. In fact, the study did
mention that it was difficult to find evidence of NGB action. Nevertheless, the study found that
NGB must work through the mitochondria and the marker for action was that the production of
superoxide decreased significantly. Since there were many limitations to this study, it is unclear
whether superoxide reduction is a valid marker for NGB action, but this will be further explored
with additional studies.
Study 3.2 was a literature review of the different mechanisms that contribute to NGB
action, especially in regards to anti-apoptosis [44]. This research understands that HIF-1 is
involved indirectly in the expression of NGB. The main transcription factors that regulate NGB
expression were found to be κB3, NFκB, and Sp1. In the presence of these factors, NGB
production is upregulated. Additionally, this article expanded upon three different modes of
NGB action: the oxygen model, the nitric oxide model, and protein-protein interactions. The
oxygen model, now considered incorrect, states that NGB can bind oxygen when reduced,
helping with oxygen transport. Like the oxygen model, the nitric oxide model states that
neuroglobin can bind nitric oxide and may even function as a nitrite reductase. However, the
study also mentioned that the role of NO and NGB has yet to be explicitly studied. Finally, the
protein-protein interactions of NGB are vast. While many proteins have been found to interact
with NGB through various research methods, one major protein is cytochrome c from the
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mitochondria. All these different markers show the presence of NGB. While this article was
compiled from different literature reviews and no experiments were conducted to find the
information, the findings were collected from reputable sources. The results will also be
confirmed with subsequent studies.
Study 3.3 is very similar to study 3.2 in that it is focused on how different brain
pathologies are mediated by NGB action through a literature review [45]. This research really
highlighted many different brain pathologies and assessed how NGB mitigates the harmful
effects, as well as any prominent trends. For example, during traumatic brain injury (TBI), NGB
levels remained elevated for six days after the introduction of TBI. This means that NGB was
still involved in the healing process for this and could still be identified after this period of time.
Even though this outcome was in relation to TBI, it could have potential effects on stroke
patients as well. Some of the markers that were found with astrocytes were inhibition of caspase
3 and 9, and the activation of the PI3K/Akt pathway. An increased level of GFAP was also
found. The interactions of NGB with different proteins were also investigated (similarly
mentioned in study 3.2). NGB was shown to interact with cytochrome c, thyroid hormone T3,
NFκB, HIF-1, erythropoietin, and VEGF. Many of these markers are similar to previous studies,
and HIF-1 has been shown multiple times to facilitate NGB expression. While many of the
findings of this study pertain to astrocytes and therefore may not provide diversity, it is still
valuable in determining NGB interactions. Overall, this study proved useful in expanding upon
the many different markers as well as the relationship between NGB and HIF-1.
Study 3.4, listed in Table 2, emphasizes the role of HIF-1 in the hypoxia response
protocol, including the cellular markers of action [46]. While not much relationship between
NGB and HIF-1 was mentioned, some of the mechanisms of HIF action were explored in this
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literature review. Below is a figure that demonstrates the proposed role of HIF in the hypoxic
response.

Figure 5: Regulation and Function of HIF-1 subunits [46]
This figure shows the different ways oxygen will regulate the two subunits of HIF: 1-𝛼 and 2-𝛼.
It also outlines the different markers and the mechanism of their action when exposed to oxygen
again. For example, in the presence of intermittent hypoxia, it will activate the 1-𝛼 subunit and
inhibit the 2-𝛼 subunit.
Source: Majmundar, A.J., W.J. Wong, and M.C. Simon, Hypoxia-inducible factors and the
response to hypoxic stress. Mol Cell, 2010. 40(2): p. 294-309.
HIF was shown to regulate erythropoietin production, which shows a potential
connection with the activity of NGB as erythropoietin was mentioned as a marker for NGB
action. The two best markers that were cited for HIF are sirtuins and intermittent hypoxia.
Sirtuins are a class of deacetylases that are involved in gene transcription and DNA repair.
Intermittent hypoxia is when cells are exposed to fluctuating cycles of normoxia and hypoxia.
HIF is thought to be transcribed mainly under conditions of loss of oxygen levels. As such, O2
sensors such as PHDs, FIH1, and the mitochondria are essential in helping to initiate HIF
transcriptional activity. A minor drawback of this study is that it focused on HIF in the whole
body, not just the nervous system, so some of these findings may not pertain to the condition of
stroke. Overall, this study helped to gain insight into the function of HIF as well as its mode of
action.
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Study 3.5 explores the relationship between NGB and two different hypoxia factors: HIF
and Nrf2 [14]. This study was cited earlier in regard to the structure and mechanism of action of
NGB, including the role of oxygen and HIF-1. Upon further review of this study, more
information about HIF-1, in particular, was learned. In fact, this research corroborates the use of
PHDs as oxygen sensors to stabilize HIF for action. Additionally, a direct relationship between
NGB and HIF/Nrf2 was found. When there is a decrease in the levels of NGB, this also leads to
a decrease in HIF and Nrf2. An experiment was performed on rats to see how NGB reacted to
the hypoxia. However, the manner of creating a hypoxic condition was very different from that
described in Aim 2. This experiment used hypobaria (decrease in pressure) to induce stress, but
this could have also introduced many uncontrolled variables. Since this experiment was
performed on the harvested brains of rats, these subjects may not provide the most accurate
results that can be extrapolated to human brains. In the end, it was found that NGB inhibited
caspase 3 and cytochrome c, which supports findings from previous studies. Overall, this
experiment helped connect many of the gaps between all five of the studies reviewed.
Graph 1 was made from the data of Table 2. All of the markers mentioned in the
"NGB/HIF-1 Findings" column of Table 2 are listed across the X-axis of the graph. A tally of the
number of studies that supported the use of that particular marker was recorded. A minimum of
one study was required for the marker to be listed on the graph. A maximum of five studies was
possible. The Y-axis lists the frequency of the marker—as in, how many studies supported and
confirmed the use of the marker. The thick green bar separates the data into two parts. The left
side of the green bar represents markers for NGB, while the right side of the green bar lists
markers that were specific to HIF-1 action. There are definitely fewer markers for HIF function
as only two studies explicitly mentioned these markers. However, all five studies had some
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connections to NGB, so it is why there are more markers for NGB. Additionally, this research
focuses on the potential benefits of NGB, so more attention was given to studies focused on
NGB rather than HIF-1. The graph shows that the most popular marker of NGB action was HIF1, which was expected since the function of the two proteins is strongly interwoven. On the HIF
side of the graph, the most acknowledged factor for HIF action was PHDs. This graph is simply
a visual representation to help condense the most essential information from Table 2 into an
easy-to-understand manner.
Overall, all these five studies taken together provide insight into the action and regulation
of both NGB and HIF-1. First, even though many of the studies that were picked were mainly a
literature review of previous research on the topic, they provided a succinct account of findings
and research that had already been performed. Together, as seen in Graph 1, the most prominent
marker of NGB action is HIF-1, and for HIF-1, the markers are PHDs. This means that once the
cells have been exposed to hypoxia, and NGB has been administered, these are the markers that
will be analyzed to ensure that NGB has conferred its neuroprotective effect on the cells.
Originally, the experimental design for this aim included testing markers of HIF-1 to see
if recovery via NGB had taken place. After the exosomes containing NGB were introduced to the
stressed cells in Aim 2, the recovery itself would be measured using HIF-1, because it has been
shown to serve as a cellular marker for NGB action. This literature review aids in this process
because it reinforces the idea that HIF-1 is a potent cellular marker to measure the action of NGB
while also providing other cellular markers that can be investigated. In order to determine the
presence of these markers, a western blot would be the best way to ensure that these markers
were present because it gives both antibody and size confirmation.
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It is important to note that this is simply a literature review of various studies. As
mentioned before, many of these studies did not perform any actual experimentation. Therefore,
these results do need to be confirmed with a physical experiment to guarantee that they are valid.
They provide a good starting point to generate hypotheses to direct further research.
Additionally, the results may vary when these experiments are performed in vitro, and the
findings may lead to entirely different pathways in vivo. Therefore, the most accurate results can
only be obtained following physical experimentation. Overall, since the markers of both NGB
and HIF-1 were collected, Aim 3 was satisfied as well.
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EXTENSIONS AND FUTURE STUDIES
Acknowledging that the scope of this thesis is somewhat limited, there are many potential
extensions to this research that can be performed to either find similar or contrasting results.
Outlined below are only a few studies that can be performed to further this research and this
topic. Further research will help either confirm or revise the information provided in this thesis
and could also help generate additional research areas or interests.
The research performed in Aim 1 was executed in vitro in a laboratory environment.
These conditions are different from the ones found physiologically in the body. Therefore, an in
vivo study on rats or mice may provide more physiologically relevant data. While these animals
are not going to provide the same environment as the human body, they can show how the results
may shift if in the presence of an actively respiring situation.
Another extension would be to use different cell types. Some of the literature mentioned
used SY5Y and astrocytes. These cell types may prove useful in assessing the role of NGB in
hypoxic conditions. Additionally, each of these cell types may even provide new insight into the
mechanism of action of NGB. Not only that, but further research could also be conducted on
cells outside the nervous system. While NGB has been shown to be localized in the brain and
spinal cord, the effects of NGB can be observed outside of this as well. For example, this can
help determine if the basal levels of NGB action detected in HEK-293 wild-type cells are valid.
In this thesis, the vector for NGB that was used was XPAK-NGB. This vector will pack
the protein inside the cell. However, another vector that could be used is XSTMP-NGB. This
will direct the NGB to be on the surface of the cell. This may change the administration of NGB
and may even have an impact on the way it confers neuroprotection on cells. Additionally, some
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of the antibodies and modes of detection for NGB may have to be altered to confirm its presence.
It may help determine if one vector is easier to work with and provides better data than the other.
While it is clearly best if this experiment had been able to be carried out as expected,
there are certain adjustments that can be made to the experimental design to test a different
hypothesis. For example, currently, NGB would be exposed to the neuronal cells after they were
placed into hypoxic conditions. From there, the effects would be measured after introducing
NGB to the sample of cells. However, another way to perform this experiment would be to
introduce the exosomal NGB to the cells before they are exposed to the hypoxic conditions. This,
contrasted with a control group, would help determine whether NGB can be used as a
preventative measure rather than a treatment alternative.
These are only a few potential extensions to this thesis. These will help widen the scope
of this research and explore different possibilities for additional research. The hope is that this
research will encourage further experimentation and provide valuable data to change the
direction of future research.
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CONCLUSION
In summary, the goal of this thesis is to demonstrate the relationship between neuroglobin
and the HIF-1 transcription factor. A hypoxic chamber, along with various assays, can help
elucidate the exosomal component of neuroglobin delivery to ischemic cells. Exosomes are able
to cross the blood-brain barrier and, therefore, can directly affect neuronal cells and serve as a
novel target for therapeutic solutions for stroke patients.
It was found that NGB is able to be packaged into the exosomes following a transfection
and exosome precipitation. HEK-293 cells may express basal levels of NGB, but the cells that
have been transfected with NGB show a much higher level of expression. The exosomes that
were precipitated also showed that NGB was present. Therefore, NGB is able to be packaged
within the exosomes and eventually delivered.
A literature review was conducted to determine what conditions of hypoxia would be best
for cell viability. Many different studies used different conditions and cell types, but after
review, the neuronal cells would be exposed to 5-15 minutes of 1% oxygen in 5% carbon dioxide
to induce hypoxia. In order to confirm that the cells were experiencing a lack of oxygen, a
western blot focused on hypoxia markers would have to be performed. The presence of these
markers would confirm that the cells are in an oxygen deprivation condition.
Following this, the stressed cells would be placed in media that also contained NGB
exosomes. The hope would be that NGB in the exosomes would still confer the neuroprotective
effects onto the hypoxic cells. This would be tested with a western blot.
To confirm this, another literature review was conducted to see what markers of NGB
and HIF-1 constituted their action. Some of the studies were focused on NGB, while other
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studies were focused on HIF-1 markers. Gathering the data together, the most efficient marker
for NGB action was HIF-1, and in turn, the marker for HIF-1 was found to be PHDs. If NGB
were able to act upon the stressed neuronal cells, these markers would show up in a western blot
when tagged with their respective antibodies. Since literature reviews still need to be supported
with physical experimentation, it is vital to understand the limitations of this particular research.
Put together, this experiment can show whether exosomal delivery of NGB can restore
proper cellular function, especially in the cases of stroke. This research can kickstart the potential
for drug delivery through these extracellular vesicles for other pathologies as well. While the
action of NGB has been well-documented, the association between NGB and exosomes provides
a novel approach.
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APPENDIX: RESEARCH PROTOCOLS
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This appendix lists the experimental protocols for Aim 1.
Aim 1.1: Collect XPAK – NGB DNA
Bacterial Miniprep:
Performed with the QIAgen Bacterial Miniprep Kit
1. The bacterial cultures were incubated overnight at 37ºC.
2. Cultures were spun down at 3000 rpm for 10 mins at room temperature.
3. The supernatant was discarded, and the pellet was resuspended in 1 ml of molecular
grade water.
4. The bacterial suspension was moved to a 1.5 ml microcentrifuge tube.
5. The sample was spun down at 13,000 rpm for 1-1.5 mins. Excess liquid was dumped.
6. The pellet was resuspended in 250 ml P1 suspension buffer.
7. 250 ml of P2 lysis buffer was added, and the microcentrifuge tube was gently inverted six
times to mix.
8. 350 ml of N3 neutrality buffer was added, and the tube was inverted to mix.
9. The sample was spun down at 13,000 rpm for 10 mins.
10. 750-800 µl of the supernatant was added to the DNA spin column.
11. The column was spun down at 13,000 rpm for 1-1.5 mins. Flowthrough was discarded.
12. 800 µl of the P.E. wash buffer was added to the column.
13. Again, the column was spun down at 13,0000 rpm for 1-1.5 mins. Flowthrough was
discarded. This step was repeated to remove traces of the wash buffer.
14. The spin column was transferred to a fresh 1.5 ml microcentrifuge tube.
15. 100 µl of E.B. elution buffer was added to the column.
16. Incubate column for five minutes at room temperature.
17. Spin the column at 13,000 rpm for 4-5 mins. Collect the DNA and discard the culture.
18. Quantify the DNA with a nanodrop.
Aim 1.2: Transfect HEK cells with XPAK-NGB DNA
Cell culture/seeding:
1.
2.
3.
4.
5.

HEK-293 cells were grown in T-75 flasks.
Cells were passaged with HEK media at 60-70% confluency.
Cells were resuspended in 1 ml of media to be seeded into a 12 well plate.
10 µl of cells were transferred to a new tube and diluted with 90 µl of fresh media.
Cells were counted, and 150,000 cells were added to each well. Cells were incubated.
Transfection with Lipofectamine 2000:

1.
2.
3.
4.

Two 1.5 ml microcentrifuge tubes were labeled Tube A and Tube B.
Tube A contained 125 µl of OptiMEM and 1 µl of Lipofectamine 2000.
Tube B contained 125 µl of OptiMEM with 1 µg of XPAK-NGB DNA (Clone 4).
Both tubes were incubated at room temperature for 10 minutes.
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5. The contents of Tube A were added to Tube B dropwise. Tubes were inverted 6 to 7
times to mix.
6. Tubes were incubated at room temperature for 20 minutes so that the DNA complex
could form.
7. While the tubes were incubating, spent media from the 12 well plate was removed, and
fresh media was added.
8. The A+B mixture was added to each well, dropwise. The plate was swirled gently to mix.
9. The plate was set in the incubator at 37ºC.
Immunocytochemistry (ICC):
Day 1:
1.
2.
3.
4.
5.

The media was removed from all wells.
500 µl of 4% PFA was added to each well to fix the cells.
The plate was incubated for 30 minutes at room temperature.
Each well was washed with PBS (3 x 5 minutes).
The PBS was removed from the wells, and 500 µl of permeabilization solution was added
per well (0.5% Triton-X in PBS).
6. The plate was incubated at room temperature for 10 minutes.
7. 500 µl of blocking solution (10% normal donkey serum in PBS) was added to each well.
8. The plate was incubated for 30 minutes at room temperature.
9. 250 µl of the primary antibody in blocking solution (1:500 dilution) was added to each
well.
10. The plate was incubated overnight at 4ºC.
Day 2:
1. Each well was washed with PBS (3 x 5 minutes).
2. 250 µl of the secondary antibody in blocking solution (1:1000 dilution) was added to
each well.
3. The plate was incubated in the dark for 2 hours.
4. 500 µl of PBS was added to each well.
5. The cells were taken for imaging.
Antibody Information:

Antibody Name
Cultured Into
Concentration

Primary Antibody
NGB (anti-NGB)
Mouse
100 µg total
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Secondary Antibody
TRITC
Donkey anti-mouse
1.5 mg/ml

Aim 1.3: Collect HEK XPAK-NGB exosomes
Exosome Precipitation:
Performed using the PEG-NaCl Precipitation Method:
Day 1:
1. Media from the transfected 12 well plate was collected and frozen over a period of one
week.
2. The frozen media was thawed in a water bath.
3. The media was transferred into 50 ml conical tubes of the same volume.
4. The tubes were spun down at 10,000 G for 30 minutes at 4ºC.
5. The supernatant was transferred to a new tube without disturbing the pellet.
6. 5 ml of 20% PEG was added for every 10 ml of culture media collected (1:2 ratio).
7. 200 µl of 7.5 M NaCl was added for every 10 milliliters of culture media collected. The
solutions were mixed by vortexing.
8. The solutions were incubated overnight.
Day 2:
1. The samples were spun down at 10,000 G for 1 hour at 4ºC.
2. The supernatant was discarded while the exosomes were present in the pellet but were not
visible.
3. The pellet was resuspended with 500 µl 1X sterile PBS.
4. The precipitated exosomes were stored at -80ºC for long-term storage.
Aim 1.4: Ensure that NGB is present in the exosomes
Dot Blot:
Day 1:
1. A small portion of the nitrocellulose membrane was cut.
2. 2 µl of each exosome sample (Transfected and wild-type exosomes) was added to the
nitrocellulose membranes.
3. The samples were dried for 15 - 20 minutes.
4. Each membrane was placed in a petri dish with 7 ml of blocking solution (5% BSA in
TBS-T).
5. The petri dishes were incubated at room temperature for one hour on a shaker.
6. The membranes were washed with TBS-T (3 x 5 min).
7. 6-7 ml of the primary antibody in blocking solution (1:500 dilution) was added to the
petri dishes.
8. The petri dishes were incubated overnight at 4ºC on a shaker.
Day 2:
1. The membranes were washed with TBS-T (3 x 5 min).
2. 6 ml of the secondary antibody in blocking solution (1:10,000 dilution) was added to the
petri dishes.
3. The petri dishes were incubated for one hour at room temperature on the shaker.
4. The membranes were washed with TBS-T (3 x 5 min).
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5.
6.
7.
8.

Some additional TBS-T was added to keep the membranes wet.
6 ml of ECL solution (1:1 ratio) was added to each petri dish.
The petri dishes were incubated for 3 minutes at room temperature.
The membranes were taken for imaging.
Antibody Information:

Antibody Name

Primary Antibody
for Exosomes
NGB (anti-NGB)

Cultured Into
Concentration

Mouse
100 µg total

Primary Antibody
for Control
Exosome anti-CD63
for Western
Mouse
0.5 µg/µL
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Secondary Antibody
Anti-mouse IgG
(HRP)
Goat anti-mouse
1.5 mg/ml
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